Immunotherapeutic Targeting of Allergic Disease

Senti, Gabriela; Gómez, Julia M. Martínez; Rettig, Lorna; Wüthrich, B; Kündig, Thomas M.; Johansen, Pål

doi:10.2174/187152806779010963

Cited by 9 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, systemic allergic reactions can occur as adverse events (AEs) against the injected material [7]. To overcome this limitation, intensive research to develop faster, safer and more convenient SIT regimens is ongoing [8].…”

Section: Introductionmentioning

confidence: 99%

Assessment of clinical efficacy of CYT003‐QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study

Klimek

Willers²,

Hammann-Haenni³

et al. 2011

Clin Experimental Allergy

131

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Assessment of clinical efficacy of CYT003‐QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study

Klimek

Willers²,

Hammann-Haenni³

et al. 2011

Clin Experimental Allergy

131

View full text Add to dashboard Cite

show abstract

“…Treating the underlying inflammation in AR requires agents that have anti-inflammatory effects and proven clinical efficacy [11]. Thus, the data provided by nasal cytology should suggest the appropriate anti-inflammatory treatment, that include as options a topical treatment with corticosteroids [14,15], or allergen specific immunotherapy in its forms of sublingual or subcutaneous administration [16][17][18], as suggested in the ARIA guidelines [7]. Fig.…”

Section: Discussionmentioning

confidence: 99%

The Clinical Stage of Allergic Rhinitis is Correlated to Inflammation as Detected by Nasal Cytology

Gelardi

Incorvaia²,

Fiorella³

et al. 2011

IADT

View full text Add to dashboard Cite

Allergic rhinitis (AR) is the most common allergic disease. The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines classify AR according to its duration and severity and suggest recommended treatments, but there is evidence that these guidelines are insufficiently followed. Considering the validity of histopathological data, physicians are more likely to be persuaded by such information on AR. Thus, we attempted to define the severity of AR by nasal cytology on the basis of the ARIA classification. We examined 64 patients with AR caused by sensitization to grass pollen. We clinically defined AR according to the ARIA classification and performed nasal cytology by Rhino-probe sampling, staining and reading by optical microscopic observation. Clinically, 22 (34.4%), 21 (32.8%), 10 (15.6%), and 11 (17.2%) patients had mild intermittent, moderate-to-severe intermittent, mild persistent, and moderate-to-severe persistent AR, respectively. Nasal cytology detected neutrophils in 49 patients, eosinophils in 41 patients, mast cells in 21 patients, and lymphocytes or plasma cells in 28 patients. The patients with moderate-to-severe AR had significantly more mast cells and lymphocytes/ plasma cells than those with mild AR. Our findings demonstrate that the ARIA classification of AR severity is associated with different cell counts in nasal cytology; especially, moderate-to-severe AR shows significantly increased counts of mast cells and lymphocyte or plasma cells. The ease of performing nasal cytology ensures is feasibility as an office AR diagnostic procedure for primary care physicians, able to indicate when anti-inflammatory treatments, such as intranasal corticosteroids and subcutaneous or sublingual allergen immunotherapy, are needed.

show abstract

“…The majority of patients are basically treated the same as patients were treated almost a century ago [30], with some modifications related to the addition of adjuvants, or chemical modification of allergens, aimed to reach a depot effect and to improve efficacy and safety of the therapy. Subcutaneous immunotherapy (SCIT) consists of the administration of increasing doses of allergen extract to which the patient is allergic.…”

Section: Current Immunotherapeutic Treatment Of Allergic Diseasesmentioning

confidence: 99%

Allergy vaccines: dreams and reality

Crameri¹

2007

Expert Review of Vaccines

View full text Add to dashboard Cite

Allergy, extrinsic asthma and atopic eczema derive from deregulated immune responses against innocuous antigens. The incidence of atopic diseases is actually affecting approximately 30% of the population in industrialized countries. Although much progress has been achieved in the development of efficient symptomatic treatments for allergic diseases, the only curative treatment remains allergen-specific immunotherapy. In contrast to classical vaccines, which elicit strong host immune responses after one or a few injections, allergen-specific immunotherapy might require a long treatment time of 3-5 years with up to 80 injections to confer some protection. The reality is that 'allergy vaccines' achieve beneficial effects through immunomodulation, which takes a long time to establish. The dream would be to develop highly efficient allergy vaccines able to cure the disease with a few injections.

show abstract

Immunotherapeutic Targeting of Allergic Disease

Cited by 9 publications

References 0 publications

Assessment of clinical efficacy of CYT003‐QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study

Assessment of clinical efficacy of CYT003‐QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study

The Clinical Stage of Allergic Rhinitis is Correlated to Inflammation as Detected by Nasal Cytology

Allergy vaccines: dreams and reality

Contact Info

Product

Resources

About